Lineage Cell Therapeutics (LCTX) opened 2026 with Q1 revenue of US$1.7 million and a basic EPS loss of US$0.02, as net income excluding extraordinary items came in at a loss of US$4.8 million. The company has seen quarterly revenue move between US$1.5 million and US$6.6 million over the past year, while EPS has ranged from a loss of around US$0.13 per share to a small profit of US$0.00 per share, presenting a mixed picture regarding the path toward better margins. For investors, the latest print keeps the focus firmly on how quickly those losses can narrow and whether the topline can carry enough weight to improve profitability.

See our full analysis for Lineage Cell Therapeutics.

With the headline numbers on the table, the next step is to see how these results line up with the prevailing narratives about growth potential, risk, and the path to profitability.

Losses on the Trailing Year Remain Heavy

• Over the last 12 months, Lineage reported total revenue of US$14.8 million against a net loss of US$64.2 million and a basic EPS loss of US$0.27, so the business is still very much loss making on a trailing basis.
• Consensus narrative points to revenue growing 58.3% annually over the next 3 years and profit margins improving from a current loss level of 436.5% to a positive 13.7%. That sits against a trailing loss of US$64.2 million and basic EPS loss of US$0.27, so investors need to weigh the promised margin turnaround against what is currently a sizeable earnings hole.
  • Analysts expecting earnings to move from a loss of US$63.5 million to a profit of US$7.9 million are effectively calling for a swing of more than US$70 million versus the recent trailing loss of US$64.2 million.
  • That same consensus implies a future P/E of 244.2x on projected earnings, which is much higher than the current P/E of 16.9x cited for the wider US biotechs industry, so the bar for that earnings path is set quite high.

Q1 2026 Resets After Strong Q4 2025

• Q1 2026 showed revenue of US$1.7 million and a net loss of US$4.8 million, compared with Q4 2025 revenue of US$6.6 million and net income of US$0.9 million, so results swung back from a profitable quarter to a loss despite the prior quarter finishing roughly at breakeven EPS.
• Bulls argue that scalable manufacturing and partnerships can support a sharp earnings improvement. However, the move from Q4 2025 profit of US$0.9 million back to a Q1 2026 loss of US$4.8 million illustrates how dependent the story still is on specific milestones showing up in the income statement.
  • The bullish view leans on forecasts of 106.7% annual revenue growth and profit margins rising from a loss level of 374.8% to a positive 7.8%, while the recent quarterly pattern shows results moving between a small profit and losses above US$4 million.
  • Optimistic analysts see earnings reaching US$7.5 million and EPS of US$0.03 by around 2028, yet current quarterly EPS is still a loss of roughly US$0.02, so there is a clear gap between where earnings stand and where that scenario expects them to go.

On a quarter that moved from a small profit back to a loss, bulls are focused on whether pipeline progress and partnerships can eventually support the kind of margin shift implied by their forecasts, and how long that might take if quarterly results remain this uneven. 🐂 Lineage Cell Therapeutics Bull Case

Valuation Signals Pull in Different Directions

• At a share price of US$1.31, Lineage trades on a P/S of 22.1x compared with a peer average of 2.6x and a US biotechs average of 10.6x. The DCF fair value is stated at US$21.12 per share, so the stock screens as both expensive on sales and heavily discounted versus that cash flow model.
• Bears highlight the combination of widening losses and a premium P/S multiple, and the contrast between a net loss of US$64.2 million over the last 12 months and a share price that still implies more than 22x trailing revenue invites questions about how quickly the business needs to move toward the consensus analyst target of US$5.14 to keep that valuation profile intact.
  • Losses have reportedly increased at about 14.7% per year over the past five years, so the high P/S comes alongside a history of earnings moving further into the red rather than toward breakeven.
  • The current price is far below the US$21.12 DCF fair value and below the US$5.14 analyst target, which means different valuation frameworks are sending very different signals while all of them have to contend with present unprofitability.

Skeptics point out that when a company posts trailing losses of more than US$60 million, a 22.1x P/S and big gaps to both DCF fair value and the US$5.14 analyst target make it especially important to understand which earnings path you find most credible before leaning too heavily on any single valuation view. 🐻 Lineage Cell Therapeutics Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Lineage Cell Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After all that, do you feel the story is leaning more bullish or cautious on Lineage? If you want to move quickly from headline impressions to your own, data driven takeaway, check the 2 key rewards

See What Else Is Out There

Lineage is still posting sizeable losses against modest revenue, with a premium P/S multiple that leans heavily on forecasts rather than established profitability.

If this mix of heavy losses and valuation tension makes you cautious, it could be worth shifting some attention toward 67 resilient stocks with low risk scores that aim to keep downside in check while you research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.